Milaboratories And Miltenyi Biotec Announce Strategic Partnership To Advance Next Generation Therapies

By Author: otis
Total Articles: 386
Comment this article

In a significant development, MiLaboratories, a prominent player in RNA immune technologies, and Miltenyi Biotec, a well-known name in biotechnology, have formed a strategic partnership that is poised to revolutionize the landscape of next-generation therapies. This collaboration will combine MiLaboratories' cutting-edge RNA kit technology for immune sequencing with Miltenyi Biotec's strong production and commercialization capabilities, marking a substantial advancement in the field.

MiLaboratories has agreed to provide Miltenyi Biotec with exclusive rights to its innovative RNA kits immune sequencing technology. This technology has played a crucial role in propelling progress in immunology and personalized medicine research. Leveraging its global presence and expertise in biotechnology, Miltenyi Biotec will be responsible for manufacturing and distributing these kits, ensuring their availability to researchers and healthcare professionals worldwide.

An important aspect of this partnership involves the incorporation of MiLaboratories' well-regarded software solutions, MiXCR and Platforma, into Miltenyi Biotec's product offerings. These software platforms are at the forefront of next-generation sequencing (NGS) data analysis, offering robust and user-friendly tools for interpreting genomic data. Customers purchasing RNA kits from Miltenyi Biotec will now have seamless access to MiXCR and Platforma, significantly enhancing their research capabilities and productivity.

Read More - https://www.techdogs.com/tech-news/business-wire/milaboratories-and-miltenyi-biotec-announce-strategic-partnership-to-advance-next-generation-therapies